Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 37, Issue 1, 2010, Pages 3-24

  Yuen, Eunice ^a,b   Gueorguieva, Ivelina ^a   Wise, Stephen ^c   Soon, Danny ^c   Aarons, Leon ^b  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Bayesian; CYP2C9; Ethnic differences; PK PD modelling; Vitamin K cycle; VKORC1; Warfarin; WinBUGS

Indexed keywords

CYTOCHROME P450 2C9; MENADIONE EPOXIDE; PROTEIN VKORC1; UNCLASSIFIED DRUG; WARFARIN;

ADULT; ALLELE; ARTICLE; ASIAN; CHINESE; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG RESPONSE; ENZYME ACTIVITY; ETHNIC DIFFERENCE; GENOTYPE; HAPLOTYPE; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; INDIAN; MALAYSIA; MALE; MOLECULAR MODEL; NORMAL HUMAN; PRIORITY JOURNAL; SIMULATION; SINGAPORE; STEADY STATE; WILD TYPE;

ADULT; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; BAYES THEOREM; COMPUTER SIMULATION; FIBRINOLYTIC AGENTS; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; NONLINEAR DYNAMICS; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; VITAMIN K 1; WARFARIN;

EID: 77949272179     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-009-9138-4     Document Type: Article

References (37)

1. Majerus P, Tollefsen D (2006) Goodman and Gilman's the pharmacological basis of therapeutics, 11th edn, Chap 54. McGraw-Hill, NY
2. R Lewis W Trager K Chan A Breckenridge M Orme M Rowland W Schary 1974 Warfarin - stereochemical aspects of its metabolism and the interaction with phenylbutazone J Clin Invest 53 1607 1617 10.1172/JCI107711 1:CAS:528: DyaE2MXotVarsw%3D%3D 4830225
3. J Miners D Birkett 1998 Cytochrome P4502C9: an enzyme of major importance in human drug metabolism Br J Clin Pharmacol 45 525 538 10.1046/j.1365-2125. 1998.00721.x 1:CAS:528:DyaK1cXktFaitro%3D 9663807 (Pubitemid 28270907)
4. M Linder 2001 Genetic mechanisms for hypersensitivity and resistance to the anticoagulant warfarin Clin Chim Acta 308 9 15 10.1016/S0009-8981(01)00420-X 1:CAS:528:DC%2BD3MXksVylsrw%3D 11412812 (Pubitemid 32537605)
5. F Zhao C Loke S Rankin J Guo H Lee T Wu T Tan T Liu W Lu Y Lim Q Zhang B Goh S Lee 2004 Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose Clin Pharmacol Ther 76 3 210 219 10.1016/j.clpt.2004.05.005 1:CAS:528:DC%2BD2cXnslKks7s%3D 15371982 (Pubitemid 39221795)
6. D Herman I Locatelli I Grabnar P Peternel M Stegnar A Mrhar K Breskvar V Dolzan 2005 Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose Pharmacogenomics J 5 193 202 10.1038/sj.tpj.6500308 1:CAS:528: DC%2BD2MXktlCmt7Y%3D 15824753 (Pubitemid 40852221)
7. B Freeman B Zhenbauer S McGrath I Borecki T Buchman 2000 Cytochrome P450 polymorphisms are associated with reduced warfarin dose Surgery 128 281 285 10.1067/msy.2000.107283 1:STN:280:DC%2BD3cvhsFOgtg%3D%3D 10923005 (Pubitemid 30623510)
8. F Kamali T Khan B King R Frearson P Kesteven P Wood A Daly H Wynne 2004 Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin Clin Pharmacol Ther 75 204 212 10.1016/j.clpt.2003.10.001 1:CAS:528:DC%2BD2cXhslenurk%3D 15001972 (Pubitemid 38314870)
9. T Li C Chang D Jin P Lin A Khvorova D Stafford 2004 Identification of the gene for vitamin K epoxide reductase Nature 427 541 544 10.1038/nature02254 1:CAS:528:DC%2BD2cXpsFWhuw%3D%3D 14765195 (Pubitemid 38209111)
10. E Sconce T Khan H Wynne P Avery L Monkhouse B King P Wood P Kesteven A Daly F Kamali 2005 The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen Blood 106 2329 2333 10.1182/blood-2005-03-1108 1:CAS:528:DC%2BD2MXhtVKqt7%2FL 15947090 (Pubitemid 41510803)
11. G D'Andrea R D'Ambrosio P Di Perna M Chetta R Santacroce V Brancaccio E Grandone M Margaglione 2005 A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin Blood 105 645 649 10.1182/blood-2004-06-2111 15358623 (Pubitemid 40070748)
12. M Rieder A Reiner B Gage D Nickerson C Eby H McLeod D Blough K Thummel D Veenstra A Rettie 2005 Effect of VKORC1 haplotypes on transcriptional regulation and warfarin Dose N Engl J Med 352 2285 2293 10.1056/NEJMoa044503 1:CAS:528:DC%2BD2MXksl2ltrk%3D 15930419 (Pubitemid 40740552)
13. S Lee S Ng J Oldenburg P Chong S Rost J Guo H Yap S Rankin H Khor T Yeo K Ng R Soong B Goh 2006 Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population Clin Pharmacol Ther 79 197 205 10.1016/j.clpt.2005.11.006 1:CAS:528: DC%2BD28XitVKhurw%3D 16513444 (Pubitemid 43297012)
14. T DeLozier S Lee S Coulter B Goh J Goldstein 2005 Functional characterization of novel allelic variants of CYP2C9 recently discovered in Southeast Asians J Pharmacol Exp Ther 315 3 1085 1090 10.1124/jpet.105.091181 1:CAS:528:DC%2BD2MXhtlalurvO 16099926 (Pubitemid 41635394)
15. S Lal E Sandanaraj S Jada MC Kong L Lee B Goh S Lee B Chowbay 2007 Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients Br J Clin Pharmacol 65 260 264 10.1111/j.1365-2125.2007.03053. x 17995970
16. L Poller D Taberner 1982 Dosage and control of oral anticoagulants: an international collaborative survey Brit J Haematol 51 479 485 10.1111/j.1365-2141.1982.tb02805.x 1:STN:280:DyaL383lslWrsQ%3D%3D
17. C Geisen M Watzka K Sittinger M Steffens L Daugela E Seifried C Müller T Wienker J Oldenburg 2005 VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation Thromb Haemost 94 773 779 16270629
18. A Blann J Hewitt F Siddiqui D Bareford 1999 Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0 Brit J Haematol 107 207 209 10.1046/j.1365-2141.1999.01672.x 1:CAS:528:DyaK1MXnsVehsLs%3D (Pubitemid 29500828)
19. H Takahashi G Wilkinson E Nutescu T Morita M Ritchie M Scordo V Pengo R Padrini I Ieiri K Otsubo T Kashima 2006 Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans Pharmacogenet Genom 16 101 110 10.1097/01.fpc.0000184955.08453.a8 1:CAS:528: DC%2BD28Xls1Gksg%3D%3D
20. D Soon P Kothare H Linnebjerg S Park E Yuen K Mace S Wise 2006 Effect of Exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian Men J Clin Pharmacol 46 1179 1187 10.1177/0091270006291622 1:CAS:528:DC%2BD28XhtFeitL%2FN 16988207 (Pubitemid 44387418)
21. L Benet BA Hoener 2002 Changes in plasma protein binding have little clinical relevance Clin Pharmacol Ther 71 3 115 121 10.1067/mcp.2002.121829 1:CAS:528:DC%2BD38XjtFChtbc%3D 11907485 (Pubitemid 34271114)
22. Pitsiu M, Parker E, Aarons L, Rowland M (1993) Population pharmacokinetics and pharmacodynamics of warfarin in healthy young adults. Eur J Pharm Sci 151-157
23. N Holford 1986 Clinical pharmacokinetics and pharmacodynamics of warfarin - understanding the dose-effect relationship Clin Pharmacokinet 11 483 504 10.2165/00003088-198611060-00005 1:CAS:528:DyaL2sXmtVKjug%3D%3D 3542339
24. X Jiang E Blair A McLachlan 2006 Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach J Clin Pharmacol 46 1370 1378 10.1177/0091270006292124 1:CAS:528:DC%2BD28Xht1Wjsb3L 17050802 (Pubitemid 44564366)
25. D Carlisle T Blaschke 1981 Vitamin K1, vitamin K1 epoxide and warfarin interrelationships in the dog Biochem Pharmacol 30 2931 2936 10.1016/0006-2952(81)90255-0 1:CAS:528:DyaL38XhvFaqtLw%3D 7317089 (Pubitemid 11031431)
26. H Bechtold D Trenk T Meinertz M Rowland E Jähnchen 1983 Cyclic interconversion of vitamin K1 and vitamin K1 2, 3-epoxide in man Br J Clin Pharmacol 16 683 689 1:CAS:528:DyaL2cXksFSqug%3D%3D 6661354
27. H Hallak P Wedlund 1992 Reversible metabolism of vitamin K-vitamin K epoxide: modeling considerations and limitations J Pharmacokinet Biop 20 1 18 10.1007/BF01143184 1:CAS:528:DyaK38Xitlaks7w%3D
28. C Vermeer 1990 γ-Carboxyglutamate-containing proteins and the vitamin K-dependent carboxylase Biochem J 266 625 636 1:CAS:528: DyaK3cXhslCit7o%3D 2183788
29. D Lunn N Best A Thomas J Wakefield D Spiegelhalter 2002 Bayesian analysis of population PK/PD models: general concepts and software J Pharmacokinet Pharmacodyn 29 271 307 10.1023/A:1020206907668 1:CAS:528:DC%2BD38XntFGrt7w%3D 12449499 (Pubitemid 35333143)
30. R Brown M Delp S Lindstedt L Rhomberg R Beliles 1997 Physiological parameter values for physiologically based pharmacokinetic models Toxicol Ind Health 13 407 484 1:CAS:528:DyaK2sXltl2itrk%3D 9249929
31. H Thijssen M Drittij-Reijnders 1993 Vitamin K metabolism and vitamin K1 status in human liver samples: a search for inter-individual differences in warfarin sensitivity Brit J Haematol 84 681 685 10.1111/j.1365-2141.1993. tb03146.x 1:CAS:528:DyaK2cXhtlaqs7Y%3D
32. Y Yamanaka M Yamano K Yasunaga T Shike K Uchida 1990 Effect of warfarin on plasma and liver vitamin K levels and vitamin K epoxide reductase activity in relation to plasma clotting factor levels in rats Thromb Res 57 205 214 10.1016/0049-3848(90)90320-C 1:CAS:528:DyaK3cXhtlaitLw%3D 2315885 (Pubitemid 20071070)
33. E Chan A McLachlan R O'Reilly M Rowland 1994 Stereochemical aspects of warfarin drug interactions: Use of a combined pharmacokinetic-pharmacodynamic model Clin Pharmacol Ther 56 3 286 294 10.1038/clpt.1994.139 1:CAS:528:DyaK2MXhvFSmtLg%3D 7924124
34. L Bodin C Verstuyft D Treguoet A Robert L Dubert C Funck-Brentano P Jaillon P Beaune P Laurent-Puig L Becquemont M Lorlot 2005 Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity Blood 106 135 140 10.1182/blood-2005-01-0341 1:CAS:528:DC%2BD2MXlvVWjsLo%3D 15790782 (Pubitemid 40967184)
35. D Veenstra J You M Rieder F Farin H Wilkerson D Blough G Cheng A Rettie 2005 Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population Pharmacogenet Genomics 15 687 691 10.1097/01.fpc.0000174789.77614.68 1:CAS:528:DC%2BD2MXpslahtLc%3D 16141794
36. L Tham B Goh A Nafziger J Guo L Wang R Soong S Lee 2005 A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9 Clin Pharmacol Ther 80 4 346 355 10.1016/j.clpt.2006.06.009
37. N Kaila R Straka R Brundage 2006 Mixture models and subpopulation classification: a pharmacokinetic simulation study and application to metoprolol CYP2D6 phenotype J Pharmacokinet Pharmacodyn 34 2 141 155 10.1007/s10928-006- 9038-9 17053980